Search
Now showing items 31-36 of 36
Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study
(1993)
Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks ...
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
(1996)
In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, ...
Cutaneous lymphocytic vasculopathy in lymphoproliferative disorders-a paraneoplastic lymphocytic vasculitis of the skin
(1995)
In this report the histopathology and the natural history of cutaneous lymphocytic vasculopathy (lymphocytic vasculitis) in patients with lymphoproliferative diseases, is described. Between January 1986 and June 1992,116 ...
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
(1997)
Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...
Second malignancies following treatment for Hodgkin's disease: A Greek experience
(1994)
The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted ...
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer
(1994)
Purpose: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. Patients and methods: Eligibility required histologically proven cancer. Patients ...